{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2681442"],"location":["China"],"study_start_month":["12"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A single-center prospective randomized controlled trial for tiggio combined with oxaliplatin (SOX) versus capecitabine combined with oxaliplatin (XELOX) in the treatment of postoperative adjuvant chemotherapy in patients with colorectal cancer","description":"Interventions: Group 1:SOX;Group 2:XELOX\nPrimary outcome(s): 3 years disease free survival rate\nStudy Design: Randomized parallel controlled trial","dates":{"creation":"2018-12-15"},"accession":"2681442","cross_references":{"Chinese Clinical Trial Register":["ChiCTR1800020419"]}}